Note 2 - Revenues

6 Months Ended

Jun. 30, 2021

Notes to Financial Statements

Revenue from Contract with Customer [Text Block]

(2) REVENUES:

The Company operates in one business segment, which primarily focuses on the development and commercialization of innovative cyclodextrin-based products for the treatment of people with serious and life threatening rare diseases and medical conditions. However, substantially all of the Company’s revenues are derived from the sale of cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. Currently, a small portion of the Company’s revenues are also generated by sales of Trappsol® Cyclo™ to South America (Brazil) for the treatment of NPC patients.

The Company considers there to be revenue concentration risks for regions where net product revenues exceed 10% of consolidated net product revenues. The concentration of the Company’s net product revenues within the regions below may have a material adverse effect on the Company’s revenues and results of operations if sales in the respective regions experience difficulties.

Revenues by product are summarized as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Trappsol® Cyclo™	$	90	$	-	$	1,930	$	30,096
Trappsol® HPB		55,753		151,188		257,101		366,150
Trappsol® Fine Chemical		166,474		55,631		308,969		133,740
Aquaplex®		11,716		928		22,992		928
Other		4,557		1,847		5,731		4,414
Total revenues	$	238,590	$	209,594	$	596,723	$	535,328

Substantially all of our sales of Trappsol® Cyclo™ for the three and six months ended June 30, 2021 and 2020 were to a single customer who exports the drug to South America. Substantially all of our Aquaplex® sales for the three and six months ended June 30, 2021 and 2020 were to one customer.